Search Result

Results for "

phosphorylated EGFR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (8) Akt (3) Amylases (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) BRK (1) Cadherin (1) ERK (2) FAK (1) Glycosidase (2) GSK-3 (1) HIV (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (2) MMP (1) NF-κB (1) PD-1/PD-L1 (1) PERK (1) PI3K (1) Reactive Oxygen Species (ROS) (1) Reverse Transcriptase (1) STAT (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Infection (1) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: EGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N4309

Lotusine	Amylases Glycosidase	Neurological Disease Metabolic Disease Cancer
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-160187A

(Rac)-AAA	Cadherin MMP Akt FAK ERK NF-κB	Cancer
(Rac)-AAA is a regulator and inhibitor targeting GPR75. By blocking the 20-HETE-induced downregulation of GPR75 expression, (Rac)-AAA effectively inhibits the activation of key downstream signaling pathways including EGFR, AKT, NF-κB and FAK. (Rac)-AAA reverses 20-HETE-mediated epithelial-mesenchymal transition, which is specifically characterized by downregulating vimentin (vimentin), upregulating E-Cadherin, as well as reducing MMP-2 activity and cancer cell migration ability. (Rac)-AAA also abolishes the 20-HETE-induced upregulation of HIC-5 expression and anchorage-independent growth, and modulates the subcellular localization of PKC-α and phosphorylated AKT. (Rac)-AAA is investigated in androgen-independent prostate cancer (castration-resistant prostate cancer) .

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

HY-164476

ES-072	EGFR GSK-3 PD-1/PD-L1	Cancer
ES-072 is an orally effective selective *EGFR* mutant (EGFR-T790M) inhibitor. ES-072 activates GSK3α by inhibiting *EGFR-T790M* activity, which promotes phosphorylation of PD-L1 at Ser279 and Ser283. The phosphorylated PD-L1 recruits the E3 ubiquitin ligase ARIH1, leading to ubiquitination and proteasomal degradation of PD-L1. This mechanism not only reduces cancer cell growth but also enhances anti-tumor immune response by lowering PD-L1 levels. ES-072 can be used to inhibit proliferation in non-small cell lung cancer (NSCLC) cells .

HY-155227S

ALK/EGFR-IN-1-d5	Isotope-Labeled Compounds EGFR Anaplastic lymphoma kinase (ALK) BRK Apoptosis Mitochondrial Metabolism	Cancer
ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of *EGFR* and ALK, with an IC₅₀ of 1.08 nM for *EGFR* and an IC₅₀ of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the *EGFR, ALK, and BRK* signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment

HY-N14349

Asterriquinone ARQ; Asterriquinone SU5504	EGFR HIV Reverse Transcriptase	Infection Cancer
Asterriquinone (ARQ), a Asterriquinone analog, is a Grb-2 binding inhibitor. Asterriquinone inhibits the Grb-2 binding activity to tyrosine phosphorylated EGFR, with an IC₅₀ of 8.37 μM. Asterriquinone is a HIV1 reverse transcriptase inhibitor with a K_i of 2.3 μM. Asterriquinone also inhibits Grb-7 and PLC-γ binding activities. .

HY-N16557

(Rac)-8-Gingerol	Apoptosis EGFR STAT PERK	Cancer
(Rac)-8-Gingerol is a non-volatile component. (Rac)-8-Gingerol can be extracted from ginger. (Rac)-8-Gingerol enhances Apoptosis. (Rac)-8-Gingerol decreases the level of phosphorylated *EGFR* and, accordingly, the phosphorylation levels of its downstream effectors, STAT3 and ERK. (Rac)-8-Gingerol exhibits anticancer activity against colorectal cancer .

HY-N4309A

Lotusine hydroxide	Amylases Glycosidase	Cardiovascular Disease
Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-181479

EGFR-IN-196	EGFR PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Cancer
EGFR-IN-196 is an *EGFR* inhibitor with an IC₅₀ of 105.96 nM. EGFR-IN-196 inhibits EGFR enzymatic activity, reduces phosphorylated PI3K levels, and suppresses downstream *EGFR-AKT* signaling. EGFR-IN-196 increases intracellular ROS generation, induces mitochondrial depolarisation, and induces apoptosis in cancer cells. EGFR-IN-196 can be used for the research of lung cancer .

HY-116091

EGFR-IN-451	EGFR Akt ERK	Cancer
EGFR-IN-451 is an EGFR inhibitor with an IC₅₀ value of 0.02 nM. EGFR-IN-451 also inhibits mutant EGFR ^L858R, EGFR ^T790M, and EGFR ^L858R/T790Mwith IC₅₀ values of 0.26-34 nM. EGFR-IN-451 inhibits AKT and ERK activation and inhibits proliferation of EGFR-mutant cancer cells. EGFR-IN-451 can be used for the research of EGFR-driven cancer .

HY-181701

EGFR-IN-202	EGFR	Cancer
EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library	4,332 compounds
Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR. MCE designs a unique collection of 4,332 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Protein Kinase Compound Library

4,332 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 4,332 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L016

Protein Tyrosine Kinase Compound Library	1,578 compounds
Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers. MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area

HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4309

Lotusine	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Amylases Glycosidase
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-N14349

Asterriquinone ARQ; Asterriquinone SU5504	Quinones Structural Classification Alkaloids Microorganisms Benzene Quinones Indole Alkaloids Source Classification	EGFR HIV Reverse Transcriptase
Asterriquinone (ARQ), a Asterriquinone analog, is a Grb-2 binding inhibitor. Asterriquinone inhibits the Grb-2 binding activity to tyrosine phosphorylated EGFR, with an IC₅₀ of 8.37 μM. Asterriquinone is a HIV1 reverse transcriptase inhibitor with a K_i of 2.3 μM. Asterriquinone also inhibits Grb-7 and PLC-γ binding activities. .

HY-N16557

(Rac)-8-Gingerol	Structural Classification Natural Products Phenols Plants Source Classification Zingiberaceae	Apoptosis EGFR STAT PERK
(Rac)-8-Gingerol is a non-volatile component. (Rac)-8-Gingerol can be extracted from ginger. (Rac)-8-Gingerol enhances Apoptosis. (Rac)-8-Gingerol decreases the level of phosphorylated *EGFR* and, accordingly, the phosphorylation levels of its downstream effectors, STAT3 and ERK. (Rac)-8-Gingerol exhibits anticancer activity against colorectal cancer .

HY-N4309A

Lotusine hydroxide	Cardiovascular Disease Alkaloids Classification of Application Fields Phenols Polyphenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Nymphaeaceae Disease Research Fields Source Classification	Amylases Glycosidase
Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

Cat. No.	Product Name	Chemical Structure

HY-155227S

ALK/EGFR-IN-1-d5
ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of *EGFR* and ALK, with an IC₅₀ of 1.08 nM for *EGFR* and an IC₅₀ of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the *EGFR, ALK, and BRK* signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment

ALK/EGFR-IN-1-d5

ALK/EGFR-IN-1-d5 (Compound (-)-9a) is a deuterated dual-target inhibitor of EGFR and ALK, with an IC₅₀ of 1.08 nM for EGFR and an IC₅₀ of 2.395 nM for ALK. ALK/EGFR-IN-1-d5 inhibits the phosphorylated proteins in the EGFR, ALK, and BRK signaling pathways, blocking the cell cycle, leading to a reduction in mitochondrial membrane potential and cell apoptosis (Apoptosis). ALK/EGFR-IN-1-d5 also significantly inhibits tumor growth in animal models and demonstrates good safety. ALK/EGFR-IN-1-d5 holds promise for research in the field of cancer treatment

Cat. No.	Product Name		Classification

HY-181701

EGFR-IN-202		Alkynes
EGFR-IN-202 is an epidermal growth factor receptor (EGFR) inhibitor that selectively targets EGFR exon 20 insertion mutations. EGFR-IN-202 can be used in research related to non-small cell lung cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

phosphorylated EGFR

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products